The annual global incidence of cervical cancer is approximately 604 000 cases/342 000 deaths, making it the fourth most common cancer in women. Cervical cancer is a major healthcare problem in low and middle income countries where 85% of new cases and deaths occur. Secondary prevention measures have reduced incidence and mortality in developed countries over the past 30 years, but cervical cancer remains a major cause of cancer deaths in women. For women who present with Fédération Internationale de Gynécologie et d’Obstétrique (FIGO 2018) stages IB3 or upwards, chemoradiation is the established treatment. Despite high rates of local control, overall survival is less than 50%, largely due to distant relapse. Reducing the health burden of cervical cancer requires greater individualization of treatment, identifying those at risk of relapse and progression for modified or intensified treatment. Hypoxia is a well known feature of solid tumors and an established therapeutic target. Low tumorous oxygenation increases the risk of local invasion, metastasis and treatment failure. While meta-analyses show benefit, many individual trials targeting hypoxia failed in part due to not selecting patients most likely to benefit. This review summarizes the available hypoxia-targeted strategies and identifies further research and new treatment paradigms needed to improve patient outcomes. The applications and limitations of hypoxia biomarkers for treatment selection and response monitoring are discussed. Finally, areas of greatest unmet clinical need are identified to measure and target hypoxia and therefore improve cervical cancer outcomes.
3 November 2020 in CardioVascular and Interventional Radiology
Introduction: The coronavirus disease 2019 (COVID-19) has created unprecedented challenges on the healthcare system. The aim of this multi-centre study was to measure the impact of COVID-19 on IR services in the UK. Material and Methods: Retrospective cross-sectional study of IR practice in six UK centres during the COVID-19 pandemic was carried out. All therapeutic IR procedures were identified using the respective hospital radiology information systems and COVID-19 status found on the hospital patient record systems. The total number of therapeutic IR procedures was recorded over two time periods, 25/03/2019–21/04/2019 (control group) and 30/03/2020–26/04/2020 (COVID-19 group). The data points collected were: procedure type, aerosol-generating nature, acute or elective case, modality used, in- or out-of-hours case and whether the procedure was done at the bedside (portable). Results: A 31% decrease in overall number of IR procedures was observed during COVID-19 compared to the control group (1363 cases vs 942 cases); however, the acute work decreased by only 0.5%. An increase in out-of-hours work by 10% was observed. COVID-19 was suspected or laboratory proved in 9.9% of cases (n = 93), and 15% of total cases (n = 141) were classed as aerosol-generating procedures. A 66% rise in cholecystostomy was noted during COVID-19. Image-guided ablation, IVC filters, aortic stent grafting and visceral vascular stenting had the greatest % decreases in practice during COVID-19, with 91.7%, 83.3%, 80.8% and 80.2% decreases, respectively. Conclusion: During the global pandemic, IR has continued to provide emergency and elective treatment highlighting the adaptability of IR in supporting other specialties.
Purpose: Hypoxia mediates treatment resistance in solid tumors. We evaluated if oxygen-enhanced MRI–derived hypoxic volume (HVMRI) is repeatable and can detect radiotherapy-induced hypoxia modification in human papillomavirus–associated oropharyngeal head and neck squamous cell cancer. Experimental Design: A total of 27 patients were recruited prospectively between March 2021 and January 2024. HVMRI was measured in primary and nodal tumors prior to standard-of-care (chemo)radiotherapy and then at weeks 2 and 4 (W2 and W4) into therapy. Two pretreatment scans assessed biomarker within-subject coefficient of variation and repeatability coefficient (RC). Cohort treatment response was measured using mixed-effects modeling. Responding lesions were identified by comparing HVMRI change with RC limits of agreement. Results: Oxygen-enhanced MRI identified hypoxia in all lesions. The HVMRI within-subject coefficient of variation was 24.6%, and RC limits of agreement were −45.7% to 84.1%. A cohort median pretreatment HVMRI of 11.3 cm3 reduced to 6.9 cm3 at W2 and 5.9 cm3 at W4 (both P < 0.001). HVMRI was reduced in 54.5% of individual lesions by W2 and in 88.2% by W4. All lesions with W2 hypoxia reduction showed persistent modification at W4. HVMRI reduced in some lesions that showed no overall volume change. Hypoxia modification was discordant between primary and nodal tumors in 50.0% of patients. Conclusions: Radiation-induced hypoxia modification can occur as early as W2, but onset varies between patients and was not necessarily associated with overall size change. Half of all patients had discordant changes in primary and nodal tumors. These findings have implications for patient selection and timing of dose de-escalation strategies in human papillomavirus–associated oropharyngeal carcinoma. See related commentary by Mason, p. 5503
1 January 2021 in CardioVascular and Interventional Radiology
The prognostic value of baseline 18F-FDG PET/CT-derived metrics in limited-stage small-cell lung cancer (LS-SCLC) remains uncertain. We evaluated whether baseline PET-derived parameters provide prognostic information beyond tumour volume and clinical factors in patients treated with curative-intent chemoradiotherapy within the phase III CONVERT trial. CONVERT was an international, multi-centre randomised controlled trial. This study is a post-hoc analysis of baseline 18F-FDG PET/CT from the multiple PET imaging parameter (MPI) cohort across 8 UK sites. PET metrics, including whole-body metabolic tumour volume (MTV), total lesion glycolysis (TLG), SUV-based measures, and radiomic features, were derived under EARL-accredited conditions. CT-derived gross tumour volume (GTV) and a pre-specified clinical prognostic model (CPM) were assessed alongside PET metrics. Overall survival (OS) and progression-free survival (PFS) were analysed using Cox regression. Incremental prognostic value beyond CPM was evaluated using Harrell’s concordance index (C-index). Correlations between imaging, clinical, and circulating tumour cell (CTC) variables were explored. Ninety-four patients comprised the MPI cohort. In univariable analyses, CPM, CT-GTV, and PET-derived MTV and TLG, were associated with shorter OS and PFS. After multivariable adjustment, only CT-GTV remained independently prognostic for OS (HR 1.36, 95% CI 1.06–1.74) and PFS (HR 1.29, 95% CI 1.03–1.63). CPM demonstrated moderate prognostic discrimination (C-index 0.63 for OS; 0.59 for PFS). Addition of SUV-based PET metrics did not improve discrimination beyond CPM (ΔC-index ≤ 0.002). PET-derived volumetric parameters were strongly correlated with CT-GTV and CPM, indicating redundancy. Circulating tumour cell counts, available in a subset, showed no significant correlations. In LS-SCLC treated with curative-intent chemoradiotherapy, baseline tumour volume is the dominant prognostic determinant. Baseline 18F-FDG PET-derived metabolic and radiomic parameters do not provide meaningful incremental prognostic value beyond tumour burden and clinical factors. While PET/CT remains essential for staging and treatment selection, its role in baseline prognostic stratification appears limited. The online version contains supplementary material available at 10.1007/s00259-026-07812-7.
Supplementary Table S2. Whole tumor volume (WTV) measurements for each lesion (T = Primary Tumor, N = Metastatic Lymph Node) and patient at the baseline (BL).